Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast
Oracle Stock Rises After Winning Up to $6.99 Billion U.S. Defense Software Contract
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad
Nvidia Reveals 9.3% Stake in AI Cloud Firm Nebius Following $2 Billion Investment
Samsung Eyes Up to $1.14 Billion Investment in AI Startup Mistral
Intel, AMD Seek Long-Term China Server CPU Deals as AI Demand Drives Supply Crunch
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand
Amkor Stock Surges 17% After $1.5 Billion Nvidia AI Packaging Partnership
Trump Administration Monitors OpenAI Incident as Lawmakers Push AI Kill Switch Bill
Scandinavian Tobacco Group Sells BREAK and Moro Brands to Japan Tobacco for €176 Million
Nike Shifts China Online Sales Strategy to Boost Brand and Fight Local Rivals
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform
Australia ASIC Tightens Auditor Oversight After KPMG Leak Scandal 



